Tandem Diabetes Care (TNDM) Free Cash Flow Growth (1y) (2014 - 2026)
Powered by 
Analysis
Tandem Diabetes Care (TNDM) Free Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.84 Bn | 174.23 Bn | 7.27 Bn | 28.87% |
| 2 | Intuitive Surgical | 128.02 Bn | 122.81 Bn | 1.96 Bn | 69.33% |
| 3 | Medtronic | 117.28 Bn | 108.46 Bn | 6.34 Bn | 120.89% |
| 4 | Stryker | 103.92 Bn | 100.44 Bn | 4.50 Bn | 14.12% |
| 5 | Boston Scientific | 63.51 Bn | 62.97 Bn | 3.85 Bn | 13.29% |
| 6 | Edwards Lifesciences | 49.96 Bn | 45.70 Bn | 1.35 Bn | 142.84% |
| 7 | Alcon | 32.86 Bn | 31.40 Bn | 1.68 Bn | -0.16% |
| 8 | Dexcom | 32.25 Bn | 30.30 Bn | 830.00 Mn | -11.68% |
| 9 | Steris | 20.74 Bn | 20.26 Bn | 684.20 Mn | -14.34% |
| 10 | Tandem Diabetes Care | 1.26 Bn | 808.29 Mn | 144.78 Mn | -157.35% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -157.35% |
| Mar 31, 2026 | 111.27% |
| Dec 31, 2025 | -59.41% |
| Sep 30, 2025 | -80.63% |
| Jun 30, 2025 | -23.26% |
| Mar 31, 2025 | -80.46% |
| Dec 31, 2024 | 161.60% |
| Sep 30, 2024 | 502.99% |
| Jun 30, 2024 | 14.30% |
| Mar 31, 2024 | 54.14% |
| Dec 31, 2023 | -6,532.64% |
| Sep 30, 2023 | -152.23% |
| Jun 30, 2023 | -162.65% |
| Mar 31, 2023 | -343.38% |
| Dec 31, 2022 | -98.61% |
| Sep 30, 2022 | -67.04% |
| Jun 30, 2022 | -119.26% |
| Mar 31, 2022 | -55.66% |
| Dec 31, 2021 | 24.67% |
| Sep 30, 2021 | 297.86% |